Study S002283

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06976619
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: RECRUITING
Enrollment: 60
Start: 2025-10-03
Primary completion: 2028-10-30
Lead sponsor: Mayo Clinic
Conditions: Type 1 Diabetes; Type 2 Diabetes
Interventions: DRUG:Liraglutide Pen Injector; OTHER:Saline Injections
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment [The change in fasting glucagon secretion rate (saline vs. exendin 9-39) in the baseline study will be compared with the change in fasting glucagon secretion rate (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)]
Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutide [The change in glucagon secretion rate during hyperglycemia (saline vs. exendin 9-39) in the baseline study will be compared with the change (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.